Bringing the fundamentals into focus…
Back to Alvotech
How Alvotech stacks up
ALVO · against 446 other Healthcare companies of similar size
Valuation
46/ 100
Below the middle of the pack.
Ranked #246 of 447 · scores higher than 44% of peers
Bars: peers in each 10-point band of the valuation score43 peers with a valuation score of 40–49, including ALVO · Click a bar to see the companies
Why valuation scores 46?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -7.7% vs peer median 0.0%
- lower earnings for the price paid: weaker than 84% of peers. Earnings yield: 1.9% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 2.6% vs peer median 4.0%
Metric by metric
Position: dot = ALVO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ALVO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 435 reported | -13.7% | 1.5% | 12% | 30% | |
| EBITDA yieldHigher is better · 448 reported | 2.6% | 4.3% | 42% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -20.6% | -0.5% | 4% | 20% | |
| Book yieldHigher is better · 437 reported | -11.8% | 37.2% | 2% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ALVOScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score